Insmed Inc (INSM)vsOramed Pharmaceuticals Inc (ORMP)

INSM

Insmed Inc

NASDAQ

$148.31

+6.59%

HEALTHCARE · Cap: $29.99B

ORMP

Oramed Pharmaceuticals Inc

NASDAQ

$3.50

+2.34%

HEALTHCARE · Cap: $141.46M

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 30221% more annual revenue ($606.42M vs $2.00M). ORMP leads profitability with a 21.9% profit margin vs -2.1%. ORMP earns a higher WallStSmart Score of 49/100 (D+).

INSM

Hold

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3

Piotroski: 6/9Altman Z: -3.77

ORMP

Hold

out of 100

Grade: D+

Growth: 5.7Profit: 5.0Value: 8.3Quality: 5.0

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for INSM.

ORMPUndervalued (+93.1%)

Margin of Safety

+93.1%

Fair Value

$46.80

Current Price

$3.50

$43.30 discount

UndervaluedFair: $46.80Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

ORMP5 strengths · Avg: 9.2/10

P/E RatioValuation

3.5x10/10

Attractively priced relative to earnings

Price/BookValuation

0.7x10/10

Reasonable price relative to book value

Return on EquityProfitability

24.5%9/10

Every $100 of equity generates 25 in profit

Profit MarginProfitability

21.9%9/10

Keeps 22 of every $100 in revenue as profit

EPS GrowthGrowth

40.9%8/10

Earnings expanding 40.9% YoY

Areas to Watch

INSM4 concerns · Avg: 3.0/10

Revenue GrowthGrowth

1.5%4/10

1.5% revenue growth

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Price/BookValuation

43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability

-2.5%2/10

ROE of -2.5% — below average capital efficiency

ORMP4 concerns · Avg: 2.0/10

Market CapQuality

$141.46M3/10

Smaller company, higher risk/reward

Revenue GrowthGrowth

-100.0%2/10

Revenue declined 100.0%

Free Cash FlowQuality

$-1.99M2/10

Negative free cash flow — burning cash

Operating MarginProfitability

-6.5%1/10

Operating margin of -6.5%

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : ORMP

The strongest argument for ORMP centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 21.9% and operating margin at -6.5%.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : ORMP

The primary concerns for ORMP are Market Cap, Revenue Growth, Free Cash Flow.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while ORMP is a declining play — different risk/reward profiles.

ORMP carries more volatility with a beta of 1.28 — expect wider price swings.

INSM is growing revenue faster at 1.5% — sustainability is the question.

ORMP generates stronger free cash flow (-2M), providing more financial flexibility.

Bottom Line

ORMP scores higher overall (49/100 vs 39/100), backed by strong 21.9% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Oramed Pharmaceuticals Inc. is dedicated to the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for the administration of polypeptides. The company is headquartered in New York, New York.

Compare with Other BIOTECHNOLOGY Stocks

INSM vs VRTX INSM vs REGN INSM vs ARGX INSM vs ALNY INSM vs ONC ORMP vs VRTX ORMP vs REGN ORMP vs ARGX ORMP vs ALNY ORMP vs ONC

Want to dig deeper into these stocks?

Full INSM Analysis →Full ORMP Analysis →